Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: Clinical perspective and significance

Michael M. Boyiadzis; Madhav V. Dhodapkar; Renier J. Brentjens; James N. Kochenderfer; Sattva S. Neelapu; Marcela V. Maus; David L. Porter; David G. Maloney; Stephan A. Grupp; Crystal L. Mackall; Carl H. June; Michael R. Bishop

doi:10.1186/s40425-018-0460-5

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: Clinical perspective and significance

Michael M. Boyiadzis, Madhav V. Dhodapkar, Renier J. Brentjens, James N. Kochenderfer, Sattva S. Neelapu, Marcela V. Maus, David L. Porter, David G. Maloney, Stephan A. Grupp, Crystal L. Mackall, Carl H. June, Michael R. Bishop

Lymphoma-Myeloma

Research output: Contribution to journal › Review article › peer-review

163 Scopus citations

Abstract

Chimeric Antigen Receptor (CAR) T cell therapies - adoptive T cell therapies that have been genetically engineered for a new antigen-specificity - have displayed significant success in treating patients with hematologic malignancies, leading to three recent US Food and Drug Administration approvals. Based on the promise generated from these successes, the field is rapidly evolving to include new disease indications and CAR designs, while simultaneously reviewing and optimizing toxicity and management protocols. As such, this review provides expert perspective on the significance and clinical considerations of CAR T cell therapies in order to provide timely information to clinicians about this revolutionary new therapeutic class.

Original language	English (US)
Article number	137
Journal	Journal for immunotherapy of cancer
Volume	6
Issue number	1
DOIs	https://doi.org/10.1186/s40425-018-0460-5
State	Published - Dec 4 2018

Keywords

Axicabtagene ciloleucel
Chimeric antigen receptor
Leukemia
Lymphoma
Tisagenlecleucel

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Molecular Medicine
Oncology
Pharmacology
Cancer Research

Access to Document

10.1186/s40425-018-0460-5

Cite this

Boyiadzis, M. M., Dhodapkar, M. V., Brentjens, R. J., Kochenderfer, J. N., Neelapu, S. S., Maus, M. V., Porter, D. L., Maloney, D. G., Grupp, S. A., Mackall, C. L., June, C. H., & Bishop, M. R. (2018). Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: Clinical perspective and significance. Journal for immunotherapy of cancer, 6(1), Article 137. https://doi.org/10.1186/s40425-018-0460-5

Boyiadzis, MM, Dhodapkar, MV, Brentjens, RJ, Kochenderfer, JN, Neelapu, SS, Maus, MV, Porter, DL, Maloney, DG, Grupp, SA, Mackall, CL, June, CH & Bishop, MR 2018, 'Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: Clinical perspective and significance', Journal for immunotherapy of cancer, vol. 6, no. 1, 137. https://doi.org/10.1186/s40425-018-0460-5

@article{48ed1c8767064f43b6bf1f0214fdc2de,

title = "Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: Clinical perspective and significance",

abstract = "Chimeric Antigen Receptor (CAR) T cell therapies - adoptive T cell therapies that have been genetically engineered for a new antigen-specificity - have displayed significant success in treating patients with hematologic malignancies, leading to three recent US Food and Drug Administration approvals. Based on the promise generated from these successes, the field is rapidly evolving to include new disease indications and CAR designs, while simultaneously reviewing and optimizing toxicity and management protocols. As such, this review provides expert perspective on the significance and clinical considerations of CAR T cell therapies in order to provide timely information to clinicians about this revolutionary new therapeutic class.",

keywords = "Axicabtagene ciloleucel, Chimeric antigen receptor, Leukemia, Lymphoma, Tisagenlecleucel",

author = "Boyiadzis, {Michael M.} and Dhodapkar, {Madhav V.} and Brentjens, {Renier J.} and Kochenderfer, {James N.} and Neelapu, {Sattva S.} and Maus, {Marcela V.} and Porter, {David L.} and Maloney, {David G.} and Grupp, {Stephan A.} and Mackall, {Crystal L.} and June, {Carl H.} and Bishop, {Michael R.}",

note = "Publisher Copyright: {\textcopyright} 2018 The Author(s).",

year = "2018",

month = dec,

day = "4",

doi = "10.1186/s40425-018-0460-5",

language = "English (US)",

volume = "6",

journal = "Journal for immunotherapy of cancer",

issn = "2051-1426",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies

T2 - Clinical perspective and significance

AU - Boyiadzis, Michael M.

AU - Dhodapkar, Madhav V.

AU - Brentjens, Renier J.

AU - Kochenderfer, James N.

AU - Neelapu, Sattva S.

AU - Maus, Marcela V.

AU - Porter, David L.

AU - Maloney, David G.

AU - Grupp, Stephan A.

AU - Mackall, Crystal L.

AU - June, Carl H.

AU - Bishop, Michael R.

PY - 2018/12/4

Y1 - 2018/12/4

N2 - Chimeric Antigen Receptor (CAR) T cell therapies - adoptive T cell therapies that have been genetically engineered for a new antigen-specificity - have displayed significant success in treating patients with hematologic malignancies, leading to three recent US Food and Drug Administration approvals. Based on the promise generated from these successes, the field is rapidly evolving to include new disease indications and CAR designs, while simultaneously reviewing and optimizing toxicity and management protocols. As such, this review provides expert perspective on the significance and clinical considerations of CAR T cell therapies in order to provide timely information to clinicians about this revolutionary new therapeutic class.

AB - Chimeric Antigen Receptor (CAR) T cell therapies - adoptive T cell therapies that have been genetically engineered for a new antigen-specificity - have displayed significant success in treating patients with hematologic malignancies, leading to three recent US Food and Drug Administration approvals. Based on the promise generated from these successes, the field is rapidly evolving to include new disease indications and CAR designs, while simultaneously reviewing and optimizing toxicity and management protocols. As such, this review provides expert perspective on the significance and clinical considerations of CAR T cell therapies in order to provide timely information to clinicians about this revolutionary new therapeutic class.

KW - Axicabtagene ciloleucel

KW - Chimeric antigen receptor

KW - Leukemia

KW - Lymphoma

KW - Tisagenlecleucel

UR - http://www.scopus.com/inward/record.url?scp=85057749342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057749342&partnerID=8YFLogxK

U2 - 10.1186/s40425-018-0460-5

DO - 10.1186/s40425-018-0460-5

M3 - Review article

C2 - 30514386

AN - SCOPUS:85057749342

SN - 2051-1426

VL - 6

JO - Journal for immunotherapy of cancer

JF - Journal for immunotherapy of cancer

IS - 1

M1 - 137

ER -

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: Clinical perspective and significance

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this